Indian Drug Makers Thrive With Focus On Catering To Poor Countries
This article was originally published in PharmAsia News
Executive Summary
Despite its relatively poor health care, India is seeing its pharmaceutical companies growing at a fast rate as they produce innovative drugs needed in poorer companies. Troikaa Pharmaceuticals is ready to launch its injectible Dynapar AQ in smaller, more-affordable doses and in poorer countries in Africa, Latin America, former Soviet republics and the European Union. Sami Labs focuses on its herb-based Ayurveda, which makes available a psoriasis treatment at only 10 percent of the cost of chemical-based drugs for the ailment. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.